Article
Subcutaneous immunoglobulin in allogeneic hematopoietic cell transplant patients
23 Feb 2021
Abstract excerpt
BACKGROUND: We evaluated feasibility, safety, and total resource use of subcutaneous immunoglobulin (SCIG) in a pilot study of patients who underwent allogeneic hematopoietic cell transplant (HCT) over a 6-month period. METHODS: A total of 20 eligible patients were treated with SCIG at 0.1 g/kg/week for up to 6 months. Patients were matched to 20 concurrent intravenous immunoglobulin (IVIG) controls. Clinical...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
